Dr. Harald Petry - CEO and co-founder
Harald has 20+ years of experience in the field of gene therapy. After his PhD on retroviruses, retroelements and cancer, he worked for 10 years at the German Primate Center on vaccines. During this time, he worked on a Polyomavirus-based gene delivery system which was transferred to Jenapharm GmbH for further development.
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Harald has 20+ years of experience in the field of gene therapy. After his PhD on retroviruses, retroelements and cancer, he worked for 10 years at the German Primate Center on vaccines. During this time, he worked on a Polyomavirus-based gene delivery system which was transferred to Jenapharm GmbH for further development.
Harald joined Jenapharm GmbH in 2000. In 2002 he joined Berlex Biosciences (US) as Project Leader. In 2007, he became the Director of Research at Amsterdam Molecular Therapeutics (AMT, which later became uniQure). In 2012 he was appointed CSO. During his 10 years at AMT/uniQure he was involved in the development of several gene therapy programs including Glybera for lipoprotein lipase deficiency. Glybera is the first gene therapy product approved in EU.
Harald holds a PhD degree from the Justus-Liebig University of Giessen (GER).
Dr. Bernard Schneider – CSO and co-founder
Bernard is a Research and Teaching Associate at the Brain Mind Institute of EPFL. Since 2017, he heads the Bertarelli Gene Therapy Platform, leading a team producing viral vectors and supporting the development of gene therapies for disorders of the central nervous system and sensory organs, including ALS. In 2006, he joined the Brain Mind Institute as senior scientist and later as a group leader in the team of Prof. Patrick Aebischer. Bernard has 16+ years of experience in Neurosciences, with a focus on translational research for the treatment of neurodegenerative disorders. He is the author of 100+ publications related to neurodegenerative diseases. He has worked on the development of AAV vectors adapted to gene therapy against familial forms of ALS, deafness and blindness. Bernard holds a PhD in Biomedical Sciences from the University of Lausanne (2001) and spent three years for postdoctoral research in Neurosciences at the University of Wisconsin in Madison, USA.
Bernard is a Research and Teaching Associate at the Brain Mind Institute of EPFL. Since 2017, he heads the Bertarelli Gene Therapy Platform, leading a team producing viral vectors and supporting the development of gene therapies for disorders of the central nervous system and sensory organs, including ALS. In 2006, he joined the Brain Mind Institute as senior scientist and later as a group leader in the team of Prof. Patrick Aebischer. Bernard has 16+ years of experience in Neurosciences, with a focus on translational research for the treatment of neurodegenerative disorders. He is the author of 100+ publications related to neurodegenerative diseases. He has worked on the development of AAV vectors adapted to gene therapy against familial forms of ALS, deafness and blindness. Bernard holds a PhD in Biomedical Sciences from the University of Lausanne (2001) and spent three years for postdoctoral research in Neurosciences at the University of Wisconsin in Madison, USA.
Patrik Richard - Corporate Secretary
Patrik is Swiss attorney-at-law and a commercial mediator at Kellerhals Carrard, Bern, largest law firm in Switzerland with over 300 lawyers.
He has a broad knowledge of the medtech and biotech business. Between 2000 and 2006 he acted as General Secretary and Secretary to the Board of Berna Biotech (formerly Swiss Serum and Vaccine Institute Berne, now a Johnson & Johnson company).He was a member of the Board of directors of Arctos Medical AG, (developing an innovative gene therapy against blindness) since its foundation in 2012 until 2019. Thereafter and until the sale to Novartis in 2021, Patrik served as Arctos' Corporate Secretary (organizing administration, IT, finance and legal). Between 2007 and 2022 Patrik acted as General Counsel of Haag-Streit Holding AG, Koeniz, Switzerland, a worldwide producer and distributor of ophthalmic medical equipment.
Since 2022 Patrik acts as Head of Operations of ReMedys Foundation, a not-for-profit organization driving a novel, collaborative approach for translational research and development for novel therapeutic options.
Patrik is Swiss attorney-at-law and a commercial mediator at Kellerhals Carrard, Bern, largest law firm in Switzerland with over 300 lawyers.
He has a broad knowledge of the medtech and biotech business. Between 2000 and 2006 he acted as General Secretary and Secretary to the Board of Berna Biotech (formerly Swiss Serum and Vaccine Institute Berne, now a Johnson & Johnson company).He was a member of the Board of directors of Arctos Medical AG, (developing an innovative gene therapy against blindness) since its foundation in 2012 until 2019. Thereafter and until the sale to Novartis in 2021, Patrik served as Arctos' Corporate Secretary (organizing administration, IT, finance and legal). Between 2007 and 2022 Patrik acted as General Counsel of Haag-Streit Holding AG, Koeniz, Switzerland, a worldwide producer and distributor of ophthalmic medical equipment.
Since 2022 Patrik acts as Head of Operations of ReMedys Foundation, a not-for-profit organization driving a novel, collaborative approach for translational research and development for novel therapeutic options.
